Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.

[1]  J. Fechner,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath‐1H , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  L. Sung,et al.  Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantations , 2007, Bone Marrow Transplantation.

[3]  N. Russell,et al.  Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  K. Weinberg,et al.  The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  R. Krance,et al.  Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  J. Kutok,et al.  Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) , 2006, Clinical Cancer Research.

[7]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[8]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[9]  R. Krance,et al.  Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) , 2005, Bone Marrow Transplantation.

[10]  M. Devidas,et al.  Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. , 2005, Blood.

[11]  R. Krance,et al.  Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab , 2005, Bone Marrow Transplantation.

[12]  C. Carlo-Stella,et al.  Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. , 2005, Experimental hematology.

[13]  H. Heslop,et al.  CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors , 2005, Bone Marrow Transplantation.

[14]  B. Salomon,et al.  Therapeutic potential of CD4+ CD25+ regulatory T cells in allogeneic transplantation. , 2005, Cytotherapy.

[15]  H. Heslop,et al.  A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells , 2004, Cancer Gene Therapy.

[16]  N. Sacchi,et al.  Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors , 2002, Leukemia.

[17]  D. Wall,et al.  Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. , 2002, Blood.

[18]  B. Storer,et al.  Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. , 2002, Blood.

[19]  R. Tsang,et al.  Single‐centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched‐related and matched‐unrelated donor transplants , 2002, British journal of haematology.

[20]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[21]  G. Hale,et al.  CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells , 2000, Bone Marrow Transplantation.

[22]  C. Pui,et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.

[23]  O. Eden.  Acute lymphoblastic leukaemia: Whom and when should we transplant? , 1999, Pediatric transplantation.

[24]  G. Hale,et al.  Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. , 1999, Blood.

[25]  M. Horowitz,et al.  Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. , 1998, Blood.

[26]  J. Falkenburg,et al.  Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. , 2006, Haematologica.

[27]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.